Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock Has Consensus Price Target of $6.75

Harvard Bioscience, Inc. (NASDAQ:HBIO) has earned an average recommendation of “Hold” from the five brokerages that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $6.75.

HBIO has been the subject of several research reports. Benchmark lifted their price target on shares of Harvard Bioscience from $6.00 to $7.50 and gave the company a “speculative buy” rating in a research report on Wednesday, August 12th. Zacks Research assumed coverage on shares of Harvard Bioscience in a report on Tuesday, November 3rd. They set a “hold” rating on the stock. StoneX lowered shares of Harvard Bioscience from a “speculative buy” rating to a “hold” rating in a research note on Wednesday. Stonex Financial cut shares of Harvard Bioscience from a “moderate buy” rating to a “hold” rating in a report on Wednesday. Finally, Weiss Ratings upgraded shares of Harvard Bioscience from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday.

Harvard Bioscience Stock Performance

Shares of Harvard Bioscience stock opened at $9.22 on Friday. The stock has a market cap of $42.14 million, a price-to-earnings ratio of -3.56 and a beta of 1.47. Harvard Bioscience has a twelve month low of $4.00 and a twelve month high of $10.20. The company’s fifty day moving average is $8.31 and its 200 day moving average is $6.57. The company has a quick ratio of 0.98, a current ratio of 1.76 and a debt-to-equity ratio of 7.28.

Harvard Bioscience (NASDAQ:HBIO) last released its quarterly earnings results on Tuesday, November 10th. The medical instruments supplier reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.27. Harvard Bioscience had a negative net margin of 13.20% and a negative return on equity of 43.94%. The firm had revenue of $22.20 million during the quarter, compared to analyst estimates of $21.80 million. Sell-side analysts forecast that Harvard Bioscience will post -2.44 EPS for the current year.

Hedge Funds Weigh In On Harvard Bioscience

An institutional investor recently bought a new position in Harvard Bioscience stock. Meros Investment Management LP purchased a new stake in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 182,992 shares of the medical instruments supplier’s stock, valued at approximately $1,125,401. Meros Investment Management LP owned about 4.02% of Harvard Bioscience at the end of the most recent reporting period. Hedge funds and other institutional investors own 80.87% of the company’s stock.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc. (NASDAQ: HBIO) develops, manufactures and supplies specialized tools, equipment and consumables used in biomedical research, drug discovery and related life science applications. Its products support work in areas such as cell biology, electrophysiology, gene delivery, organ-on-chip research and preclinical studies. The company’s portfolio includes laboratory instruments, tissue and organ perfusion systems, electrophysiology equipment, cell and molecular biology products, and related consumables.